Pioderma Gangrenoso Idiopático Tratado com Adalimumab: Um Caso de Sucesso

Nuno Gomes; Patrícia Amoedo; Ana Luísa Cunha; Filomena Azevedo; Sofia Magina

doi:10.29021/spdv.79.4.1458

Nuno Gomes Serviço de Dermatologia e Venereologia, Centro Hospitalar Universitário de São João, Porto, Portugal https://orcid.org/0000-0003-4278-3106
Patrícia Amoedo Serviço de Dermatologia e Venereologia, Centro Hospitalar Universitário de São João, Porto, Portugal https://orcid.org/0000-0003-0354-7127
Ana Luísa Cunha Serviço de Medicina Interna, Centro Hospitalar Universitário de São João, Porto, Portugal https://orcid.org/0000-0001-6274-0360
Filomena Azevedo Serviço de Dermatologia e Venereologia, Centro Hospitalar Universitário de São João, Porto, Portugal https://orcid.org/0000-0003-0402-6382
Sofia Magina Serviço de Dermatologia e Venereologia, Centro Hospitalar Universitário de São João, Porto, Portugal; Faculdade de Medicina, Universidade do Porto, Portugal https://orcid.org/0000-0002-9185-0216

DOI: https://doi.org/10.29021/spdv.79.4.1458

Keywords: Adalimumab, Pyoderma Gangrenosum/drug therapy

Downloads

Download data is not yet available.

References

- Marzano AV, Borghi A, Wallach D, Cugno M. A Comprehensive Review of Neutrophilic Diseases. Clin Rev Allergy Immunol. 2018;54:114-130. doi: 10.1007/s12016-017-8621-8

- Kridin K, Cohen AD, Amber KT. Underlying Systemic Diseases in Pyoderma Gangrenosum: A Systematic Review and Meta-Analysis. Am J Clin Dermatol. 2018;19:479-487. doi: 10.1007/s40257-018-0356-7

- Abdallah HB, Fogh K, Bech R. Pyoderma gangrenosum and tumour necrosis factor alpha inhibitors: A semi-systematic review. Int Wound J. 2019;16:511-521. doi: 10.1111/iwj.13067

- Maverakis E, Ma C, Shinkai K, Fiorentino D, Callen JP, Wollina U, et al. Diagnostic Criteria of Ulcerative Pyoderma Gangrenosum: A Delphi Consensus of International Experts. JAMA Dermatol. 2018;154:461-466. doi: 10.1001/jamadermatol.2017.5980

- Goldust M, Hagstrom EL, Rathod D, Ortega-Loayza AG. Diagnosis and novel clinical treatment strategies for pyoderma gangrenosum. Expert Rev Clin Pharmacol. 2020;13:157-161. doi: 10.1080/17512433.2020.1709825

- Rousset L, Masson A, Begon E, Villani A, Battistella M, Rybojad M, et al. Tumor necrosis factor-α inhibitors for the treatment of pyoderma gangrenosum not associated with inflammatory bowel diseases: A multicenter retrospective study. J Am Acad Dermatol. 2019;80:1141-1143. doi: 10.1016/j.jaad.2018.10.006

- Brooklyn TN, Dunnill MS, Shetty A, Bowden JJ, Williams JL, Griffiths CM, et al. Infliximab for the treatment of pyoderma gangrenosum: a randomised, double blind, placebo controlled trial. Gut. 2006;55:505-9. doi: 10.1136/gut.2005.074815

- Campanati A, Brisigotti V, Ganzetti G, Molinelli E, Giuliodori K, Consales V, et al. Finally, recurrent pyoderma gangrenosum treated with Adalimumab: case report and review of the literature. J Eur Acad Dermatol Venereol. 2015;29:1245-7. doi: 10.1111/jdv.12703

Idiopathic Pyoderma Gangrenosum Treated with Adalimumab: A Case of Success

Downloads

References